Differentiated thyroid cancer primarily classified by tumor histology comprises follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC), which represent distinct malignancies regarding the pattern of tumor spreading, responsiveness to radioiodine treatment, and clinical outcome. As FTC and PTC also differ genetically i.e., RAS mutations predominate in FTC whereas mutant BRAF is much more frequent in PTC, it is assumed although yet unproven that the archetypical tumor growth pattern – follicular versus papillary – depends on mutation identity and potentially the graded signaling output of the MAPK pathway that differs in response to constitutive activation by RAS or BRAF. In this study, we show by clonal tracing in mice carrying a Braf mutant allele with targeted expression of BRAFV600E exclusively in the thyroid gland that sporadically developed tumors either adopt a follicular or a papillary phenotype depending on follicle origin. Moreover, a single tumor clone may transit from papillary to follicular growth associated with asymmetric distribution of stromal tissue in the immediate vicinity of the tumor. Key to these observations is monitoring the progeny of cells undergoing spontaneous recombination of both BrafCA and the reporter gene because of Cre leakage which, in contrast to after induced oncogene activation comprising all target cells, implies that tumors develop stochastically and asynchronously originating from a limited number of BRAF mutant cells and taking place within a preserved thyroid tissue microenvironment. The results suggest that the natural heterogeneity of follicles and tumor cell plasticity modify BRAFV600E-induced neoplastic growth leading to divergent tumor histogenesis. Significance: Cell-of-origin intrinsic features rather than driver mutation identity influence tumor growth patterning in differentiated thyroid cancer and might impact histopathologic diagnosis of thyroid carcinoma subtypes.
Comparison of tamoxifen-induced and noninduced thyroid tumorigenesis in Tg-CreERT2;BrafCA/+ mice. Representative images of histology and IHC staining of Tg and CRE recombinase. A and B, Thyroid lobe of wild-type (WT) animals. Normal follicular tissue (A) and uniform accumulation of Tg in follicle lumina (B). C–E, General neoplastic changes in the thyroid of Tg-CreERT2;BrafCA/+ mice injected with Tam after weaning. Gross lobe enlargement (A) and loss of Tg expression in cells (D and E); E shows the high power of the boxed area in D. Of note, the follicle lumina is largely empty of Tg. F and G, Heterogeneous neoplastic alterations due to spontaneous BrafCA activation in Tg-CreERT2;BrafCA/+ mice devoid of Tam injections. Loss of Tg expression in neoplastic cells and preserved Tg expression in nonneoplastic follicles (F and G). F shows the high power of the boxed area in G. Arrowheads indicate Tg+ cells. H–J, Loss of CRE expression in neoplastic cells; J shows the high power of the boxed area in I. Asterisks (in H) mark CRE-negative neoplastic follicles. Arrows (in H and I) indicate residual CRE+ cells. Tam, tamoxifen; f, follicle; inj, injection. Bars: 500 (A–D and F), 100 (G–I), and 50 (E and J) μm.
Papillary–follicular transition in BrafCA-induced PTC. Advanced tumor stage of a 12-month-old noninduced Tg-CreERT2;BrafCA/+;mTmG mouse. Both thyroid lobes were serially sectioned from pole to pole for comprehensive evaluation. A–C, Overview of tumors present in the left thyroid lobe (encircled); transverse tissue section (A), 3D reconstruction (B), and schematic representation (C) of the predominant mT+ tumor clone (1) and associated mG+ clones (2–5). D–F, Distal/dorsal domain (D), proximal/ventral domain (E), and schematic representation (F) of mG+ clone 3. Arrows and arrowheads indicate outward evaginations and inward papillary formations, respectively, in consecutive segments of the same neoplastic epithelium of a giant follicle. Asterisks indicate follicular differentiation of emigrating mG+ tumor cells. Directions of continuity of clone 3 are indicated by green-colored arrows (in D and E). DAPI stained nuclei (in A, D and E). e, esophagus; t, trachea; s, stromal tissue of tumor. Bars: 500 (A) and 100 (D and E) μm.
Clonal tracing of thyroid tumor development in noninduced Tg-CreERT2;BrafCA/+;mTmG mice. Reporter gene activation designated by switch from mTomato (mT+) to mGFP (mG+) expression was monitored by fluorescence microscopy. Induced Cre-mediated recombination served as controls for comparison. A and B, Normal thyroid tissue, overview (A) and high power (B), after tamoxifen treatment of control mice devoid of BrafCA. Arrows indicate scarce presence of mT+ cells escaping induced mTmG activation. C, Clusters of enlarged/neoplastic follicles exclusively containing mT+ (encircled) or mG+ cells in a Braf mutant mouse devoid of tamoxifen induction. Boxed areas are shown to the right for magnification. Arrowheads indicate single mG+ cells present in an adjacent normal follicle (asterisk). D and E, Widespread induction of mG+ thyroid cells in tamoxifen-injected mutant mice; representative image (D) and quantitation (n = 3; E). F and G, Escape from tamoxifen-induced reporter gene activation in neoplastic follicles and papillary tumor. Arrow (in F) indicates origin of tumor derived from a mT+ follicle; arrowheads indicate sparse mG+ activation among tumor cells. Colored arrows (in G) demarcate dual clonal origin of neoplastic follicle (encircled) distinguished by the presence or absence of reporter gene activation. H, Predicted labeling of tumor cell progeny depending on whether mTmG is stochastically activated before BrafCA activation (to the left) or hypothetically in cells in which BrafCA is already activated and the resulting downregulation of the Cre driver (the Tg promoter) prevents further Cre-mediated recombination, i.e., of the reporter gene (to the right). Bars: 500 (A and C), 100 (D and F) 50 (G), and 25 (B) μm.